{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:27:08Z","timestamp":1768829228597,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005389","name":"Universit\u00e0 degli Studi dell'Insubria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>In randomized clinical trials (RCTs) of nonvitamin K antagonist oral anticoagulants (NOACs) for acute venous thromboembolism (VTE),\u2009~\u200912\u201313% of patients were elderly and\u2009~\u200926% had mild-to-moderate renal impairment. Observational studies are not restricted by the selection and treatment criteria of RCTs. In this ancillary analysis of the RE-COVERY DVT\/PE global observational study, we aimed to describe patient characteristics, comorbidities, and anticoagulant therapy for subgroups of age (&lt;\u2009or\u2009\u2265\u200975\u00a0years) and renal impairment (creatinine clearance [CrCl; estimated with Cockcroft\u2013Gault formula]\u2009&lt;\u200930 [severe], 30 to\u2009&lt;\u200950 [moderate], 50 to\u2009&lt;\u200980 [mild],\u2009\u2265\u200980 [normal] mL\/min). Of 6095 eligible patients, 25.3% were aged\u2009\u2265\u200975\u00a0years; 38.2% (1605\/4203 with CrCl values) had mild-to-moderate renal impairment. Comorbidities were more common in older patients (73.9% aged\u2009\u2265\u200975 vs. 58.1%\u2009&lt;\u200975\u00a0years) and in those with mild or moderate versus no renal impairment (75.9%, 80.9%, and 59.3%, respectively). At hospital discharge or 14\u00a0days after diagnosis (whichever was later), most patients (53.7% and 55.1%, respectively) in both age groups received NOACs; 20.8% and 23.4%, respectively, received vitamin K antagonists, 19.0% and 21.8% parenteral therapy, 2.3% and 3.8% other anticoagulant treatments. Use of NOACs decreased with worsening renal impairment (none 58.5%, moderate 49.6%, severe 25.7%) and, in younger versus older patients with moderate renal impairment (33.1% vs. 56.1%). In routine practice, there are more elderly and renally impaired patients with VTE than represented in RCTs. Decreasing renal function, but not older age, was associated with less NOAC use. Clinical Trial Registration: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>. Unique identifier: NCT02596230.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphic abstract<\/jats:title>\n                <jats:p>Decreasing renal function, particularly in the subgroup with CrCl\u2009&lt;\u200930\u00a0mL\/min, but not older age, was associated with less use of nonvitamin K antagonist oral anticoagulants (NOACs). Nevertheless, more than half of the older patients with moderate renal impairment received a NOAC as their oral anticoagulant.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11239-020-02239-9","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T19:02:47Z","timestamp":1598468567000},"page":"561-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT\/PE study"],"prefix":"10.1007","volume":"51","clinical-trial-number":[{"clinical-trial-number":"nct02596230","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-8879","authenticated-orcid":false,"given":"Walter","family":"Ageno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan B.","family":"Casella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kok Han","family":"Chee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Schellong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Desch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Voccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Zint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"issue":"5","key":"2239_CR1","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1160\/TH08-04-0255","volume":"100","author":"FA Spencer","year":"2008","unstructured":"Spencer FA, Gore JM, Lessard D, Emery C, Pacifico L, Reed G, Gurwitz JH, Goldberg RJ (2008) Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost 100(5):780\u2013788. https:\/\/doi.org\/10.1160\/TH08-04-0255","journal-title":"Thromb Haemost"},{"issue":"5","key":"2239_CR2","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/ckj\/sfu080","volume":"7","author":"S Hughes","year":"2014","unstructured":"Hughes S, Szeki I, Nash MJ, Thachil J (2014) Anticoagulation in chronic kidney disease patients-the practical aspects. Clin Kidney J 7(5):442\u2013449. https:\/\/doi.org\/10.1093\/ckj\/sfu080","journal-title":"Clin Kidney J"},{"issue":"2","key":"2239_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315\u2013352. https:\/\/doi.org\/10.1016\/j.chest.2015.11.026","journal-title":"Chest"},{"issue":"9","key":"2239_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, AMPLIFY Investigators (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507","journal-title":"N Engl J Med"},{"issue":"26","key":"2239_CR5","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S, for the EINSTEIN Investigators (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510. https:\/\/doi.org\/10.1056\/NEJMoa1007903","journal-title":"N Engl J Med"},{"issue":"14","key":"2239_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR Buller","year":"2012","unstructured":"Einstein-PE Investigators, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287\u20131297. https:\/\/doi.org\/10.1056\/NEJMoa1113572","journal-title":"N Engl J Med"},{"issue":"24","key":"2239_CR7","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342\u20132352. https:\/\/doi.org\/10.1056\/NEJMoa0906598","journal-title":"N Engl J Med"},{"key":"2239_CR8","unstructured":"European Medicines Agency. Dabigatran. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf. Accessed 6 Apr 2020"},{"key":"2239_CR9","unstructured":"European Medicines Agency. Edoxaban. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002629\/WC500189045.pdf. Accessed 6 Apr 2020"},{"key":"2239_CR10","unstructured":"Electronic Medicines Compendium. Rivaroxaban. Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/25586. Accessed 6 Apr 2020"},{"key":"2239_CR11","doi-asserted-by":"publisher","unstructured":"Goldhaber SZ, Ageno W, Casella IB, Chee KH, Schellong S, Singer DE, Desch M, Reilly PA, Donado E, Tang W, Voccia I, Schulman S (2020) Profile of patients diagnosed with acute venous thromboembolism in routine clinical practice: the RE-COVERY DVT\/PE\u2122 study. Am J Med\u00a0133(8):936\u2013945 https:\/\/doi.org\/10.1016\/j.amjmed.2020.03.036","DOI":"10.1016\/j.amjmed.2020.03.036"},{"issue":"2","key":"2239_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1160\/TH16-07-0566","volume":"117","author":"W Ageno","year":"2017","unstructured":"Ageno W, Casella IB, Han CK, Raskob GE, Schellong S, Schulman S, Singer DE, Kimura K, Tang W, Desch M, Goldhaber SZ (2017) RE-COVERY DVT\/PE: rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost 117(2):415\u2013421. https:\/\/doi.org\/10.1160\/TH16-07-0566","journal-title":"Thromb Haemost"},{"issue":"5","key":"2239_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1538-7836.2007.02507.x","volume":"5","author":"LM Cook","year":"2007","unstructured":"Cook LM, Kahn SR, Goodwin J, Kovacs MJ (2007) Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost 5(5):937\u2013941. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02507.x","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2239_CR14","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1160\/TH17-03-0176","volume":"117","author":"SZ Goldhaber","year":"2017","unstructured":"Goldhaber SZ, Schulman S, Eriksson H, Feuring M, Fraessdorf M, Kreuzer J, Schuler E, Schellong S, Kakkar A (2017) Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II. Thromb Haemost 117(11):2045\u20132052. https:\/\/doi.org\/10.1160\/TH17-03-0176","journal-title":"Thromb Haemost"},{"issue":"15","key":"2239_CR15","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR Buller","year":"2013","unstructured":"Hokusai VTE Investigators, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406\u20131415. https:\/\/doi.org\/10.1056\/NEJMoa1306638","journal-title":"N Engl J Med"},{"issue":"2","key":"2239_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1055\/s-0038-1676611","volume":"119","author":"W Ageno","year":"2019","unstructured":"Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Pieper KS, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK (2019) Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE Registry. Thromb Haemost 119(2):319\u2013327. https:\/\/doi.org\/10.1055\/s-0038-1676611","journal-title":"Thromb Haemost"},{"issue":"8","key":"2239_CR17","first-page":"1046","volume":"91","author":"L Lopez-Jimenez","year":"2006","unstructured":"Lopez-Jimenez L, Montero M, Gonzalez-Fajardo JA, Arcelus JI, Suarez C, Lobo JL, Monreal M, Investigators RIETE (2006) Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 91(8):1046\u20131051","journal-title":"Haematologica"},{"key":"2239_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.thromres.2017.10.011","volume":"160","author":"M Rattazzi","year":"2017","unstructured":"Rattazzi M, Villalta S, De Lucchi L, Sponchiado A, Galliazzo S, Faggin E, Pagliara V, Zilli C, Callegari E, Caberlotto L, Puato M, Pauletto P (2017) Chronic kidney disease is associated with increased risk of venous thromboembolism recurrence. Thromb Res 160:32\u201337. https:\/\/doi.org\/10.1016\/j.thromres.2017.10.011","journal-title":"Thromb Res"},{"key":"2239_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1477-9560-12-25","volume":"12","author":"RM Bauersachs","year":"2014","unstructured":"Bauersachs RM, Lensing AW, Prins MH, Kubitza D, Pap AF, Decousus H, Beyer-Westendorf J, Prandoni P (2014) Rivaroxaban versus enoxaparin\/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J 12:25. https:\/\/doi.org\/10.1186\/1477-9560-12-25","journal-title":"Thromb J"},{"issue":"7","key":"2239_CR20","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C, Re-Cover II Trial Investigators (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764\u2013772. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.004450","journal-title":"Circulation"},{"issue":"4","key":"2239_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1160\/th16-03-0244","volume":"116","author":"P Verhamme","year":"2016","unstructured":"Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MP, Cohen AT, Meyer G, Grosso MA, Raskob G, Weitz JI, Zhang G, Buller H (2016) Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost 116(4):747\u2013753. https:\/\/doi.org\/10.1160\/th16-03-0244","journal-title":"Thromb Haemost"},{"issue":"4","key":"2239_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.thromres.2014.06.020","volume":"134","author":"A Gomez-Outes","year":"2014","unstructured":"Gomez-Outes A, Terleira-Fernandez AI, Lecumberri R, Suarez-Gea ML, Vargas-Castrillon E (2014) Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res 134(4):774\u2013782. https:\/\/doi.org\/10.1016\/j.thromres.2014.06.020","journal-title":"Thromb Res"},{"issue":"12","key":"2239_CR23","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","volume":"124","author":"N van Es","year":"2014","unstructured":"van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968\u20131975. https:\/\/doi.org\/10.1182\/blood-2014-04-571232","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02239-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-020-02239-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02239-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T23:21:33Z","timestamp":1629933693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-020-02239-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2239"],"URL":"https:\/\/doi.org\/10.1007\/s11239-020-02239-9","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"26 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Ageno has participated in advisory boards for Bayer, Portola, Aspen, Sanofi, Daiichi Sankyo, Boehringer Ingelheim, and has received travel or research support from Bayer, Portola, Aspen, Janssen, Sanofi, Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, and Boehringer Ingelheim. Dr. Casella has received speaker and\/or consultancy fees from Boehringer Ingelheim, Bayer, Daiichi Sankyo, Pfizer, and Amgen. Dr. Chee has received speaker fees from Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer. Dr. Schellong has received speaker fees from Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Sanofi, and LEO Pharma. He has received consultancy fees from Bayer HealthCare, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, and Sanofi. Dr. Schulman has received honoraria from Alnylam, Boehringer Ingelheim, Bayer HealthCare, Daiichi Sankyo, Pfizer, and Sanofi, and research support from Boehringer Ingelheim and Octapharma. Dr. Singer has received honoraria from Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Johnson & Johnson, and Pfizer, and research support from Boehringer Ingelheim and Bristol-Myers Squibb. Dr. Desch, Dr. Tang, Dr. Voccia, and Dr. Zint are employees of Boehringer Ingelheim. Dr. Goldhaber has received research support from Boehringer Ingelheim, Bristol-Myers Squibb, Boston Scientific BTG, Daiichi Sankyo, Janssen, and the US National Heart Lung and Blood Institute. He is a consultant for Bayer and Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was carried out in compliance with the protocol and the principles laid down in the Declaration of Helsinki. In addition, the applicable sections of the guidelines for Good Clinical Practice, Good Epidemiological Practice, and Good Pharmacoepidemiology Practices, and local regulations were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients (or their legal representative) provided written informed consent before study entrance, in accordance with local regulations. No study procedures or data recording were performed unless a patient had consented to participate in the study or a waiver had been obtained in accordance with local regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}